MX2024007911A - Compuestos. - Google Patents
Compuestos.Info
- Publication number
- MX2024007911A MX2024007911A MX2024007911A MX2024007911A MX2024007911A MX 2024007911 A MX2024007911 A MX 2024007911A MX 2024007911 A MX2024007911 A MX 2024007911A MX 2024007911 A MX2024007911 A MX 2024007911A MX 2024007911 A MX2024007911 A MX 2024007911A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- synthesis
- treatment
- present disclosure
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021904268A AU2021904268A0 (en) | 2021-12-24 | Compounds | |
| PCT/AU2022/051591 WO2023115165A1 (en) | 2021-12-24 | 2022-12-23 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007911A true MX2024007911A (es) | 2024-09-10 |
Family
ID=86900872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007911A MX2024007911A (es) | 2021-12-24 | 2022-12-23 | Compuestos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163044A1 (enExample) |
| EP (1) | EP4452979A4 (enExample) |
| JP (1) | JP2025501141A (enExample) |
| KR (1) | KR20240128059A (enExample) |
| CN (1) | CN118974044A (enExample) |
| AU (1) | AU2022422215A1 (enExample) |
| CA (1) | CA3241845A1 (enExample) |
| IL (1) | IL313857A (enExample) |
| MX (1) | MX2024007911A (enExample) |
| WO (1) | WO2023115165A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2022221415A2 (en) | 2021-04-13 | 2022-10-20 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| JP2025502615A (ja) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス，インク． | フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| TW202425965A (zh) | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| EP4735441A1 (en) | 2023-06-28 | 2026-05-06 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| JP2026524104A (ja) * | 2023-06-28 | 2026-07-17 | サイロ プロプリエタリー リミテッド | 化合物 |
| WO2026030052A1 (en) | 2024-07-31 | 2026-02-05 | Fmc Corporation | Fungicidal substituted azoles |
| WO2026137050A1 (en) * | 2024-12-24 | 2026-07-02 | Psylo Pty Ltd | Compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5977131A (en) * | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| GB9819020D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| EP1513521A2 (en) * | 2002-05-30 | 2005-03-16 | Alcon, Inc. | Pyranoindazoles and their use for the treatment of glaucoma |
| US7964728B2 (en) * | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| ES2374581T3 (es) | 2006-07-06 | 2012-02-20 | Abbott Healthcare Products B.V. | Derivados de azaindol con una combinación de agonismo parcial del receptor nicotínico de la acetilcolina e inhibición de la reabsorción de dopamina. |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| PL2485731T4 (pl) * | 2009-10-06 | 2017-07-31 | Millennium Pharmaceuticals, Inc. | Związki heterocykliczne użyteczne jako inhibitory PDK1 |
| US9073851B2 (en) * | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
| WO2017125351A1 (en) | 2016-01-21 | 2017-07-27 | Laboratorios Lesvi Sl | Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole |
| CA3182093A1 (en) * | 2020-06-10 | 2021-12-16 | Florence Wagner | Tricyclic psychoplastogens and uses thereof |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
-
2022
- 2022-12-23 JP JP2024538669A patent/JP2025501141A/ja active Pending
- 2022-12-23 KR KR1020247024904A patent/KR20240128059A/ko active Pending
- 2022-12-23 CA CA3241845A patent/CA3241845A1/en active Pending
- 2022-12-23 CN CN202280091203.9A patent/CN118974044A/zh active Pending
- 2022-12-23 AU AU2022422215A patent/AU2022422215A1/en active Pending
- 2022-12-23 MX MX2024007911A patent/MX2024007911A/es unknown
- 2022-12-23 WO PCT/AU2022/051591 patent/WO2023115165A1/en not_active Ceased
- 2022-12-23 EP EP22908927.1A patent/EP4452979A4/en active Pending
- 2022-12-23 IL IL313857A patent/IL313857A/en unknown
- 2022-12-23 US US18/722,007 patent/US20250163044A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022422215A1 (en) | 2024-08-01 |
| CA3241845A1 (en) | 2023-06-29 |
| JP2025501141A (ja) | 2025-01-17 |
| WO2023115165A1 (en) | 2023-06-29 |
| KR20240128059A (ko) | 2024-08-23 |
| US20250163044A1 (en) | 2025-05-22 |
| CN118974044A (zh) | 2024-11-15 |
| EP4452979A1 (en) | 2024-10-30 |
| IL313857A (en) | 2024-08-01 |
| EP4452979A4 (en) | 2025-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| ECSP055535A (es) | Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6 | |
| ECSP055536A (es) | Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6 | |
| CA3241845A1 (en) | Compounds | |
| DOP2015000185A (es) | Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos | |
| BR112015022263A8 (pt) | n-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| CU20140082A7 (es) | Pirimidinas y triazinas fusionadas sustituidas y sus uso | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| NI202000029A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| DOP2010000078A (es) | Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3 | |
| NI200600306A (es) | Derivados de sulfamida y sulfamato para el tratamiento de la epilepsia y trastornos relacionados | |
| ECSP10010025A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| ECSP16090804A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| NI201600161A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| MX2025015490A (es) | Compuestos | |
| MX2022004473A (es) | Modificador de un derivado de anillo de cuatro miembros, metodo de preparacion y aplicacion del mismo. | |
| UY29831A1 (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos. | |
| ECSP088176A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 | |
| CL2009001282A1 (es) | Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras. | |
| DOP2005000103A (es) | Derivados de tetrahidroisoquinolinsulfonamidas. | |
| CL2022002589A1 (es) | Tratamiento de trastornos respiratorios |